ACADIA Pharmaceuticals Inc. Stock Forecast NASDAQ:ACAD

Price Target and Analyst Ratings

Most Recent Rating

On August 05, 2021 "Needham & Company LLC" gave "$30.00 - $26.00" rating for ACAD. The price target was changed from $20.05 to 4.8%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-08-05	$30.00 - $26.00	Target Lowered by	Needham & Company LLC	$19.25	$20.05→4.8%
2021-08-05	$31.00 - $28.00	Target Lowered by	SVB Leerink	$19.25	$21.05→2.7%
2021-08-05	$33.00 - $27.00	Target Lowered by	Cantor Fitzgerald	$19.25	$21.05→2.7%
2021-08-05	$29.00 - $27.00	Target Lowered by	Morgan Stanley	$19.25	$21.05→2.7%
2021-07-19		Reiterated by	SVB Leerink	$23.21	$23.21→1.2%
2021-07-10	$23.71	Target Set by	Raymond James	$23.71	$23.71+0.0%
2021-07-09		Reiterated by	Raymond James	$23.71	$23.71+0.0%
2021-07-09	Hold	Reiterated by	Raymond James	$23.71
2021-06-10	Hold	Initiated by	Berenberg Bank	$27.30	$29.00
2021-05-18	Hold	Target Raised by	Canaccord Genuity	$21.39	$26.00 → $27.00
2021-05-12	Hold	Reiterated by	Canaccord Genuity	$21.83	$26.00 → $27.00
2021-05-12	Hold	Reiterated by	Canaccord Genuity	$21.83
2021-05-12	Overweight	Target Raised by	Morgan Stanley	$21.83	$28.00 → $29.00
2021-05-12	Hold	Target Raised by	Canaccord Genuity	$21.83	$26.00 → $27.00
2021-05-06	Overweight	Target Raised by	Morgan Stanley	$20.95	$28.00 → $29.00
2021-05-06	Hold	Reiterated by	Mizuho	$20.95
2021-04-13	Buy - Neutral	Reiterated by	The Goldman Sachs Group	$20.60	$73.00 → $25.00
2021-04-13	Buy - Neutral	Reiterated by	HC Wainwright	$20.60	$43.00 → $18.00
2021-04-13	Buy - Neutral	Reiterated by	Mizuho	$20.60	$25.00
2021-04-13	Buy - Hold	Reiterated by	Canaccord Genuity	$20.60	$40.00 → $26.00
2021-04-13	Overweight	Target Lowered by	Morgan Stanley	$20.60	$50.00 → $28.00
2021-04-13	Buy - Hold	Reiterated by	Jefferies Financial Group	$20.60	$40.00 → $21.00
2021-04-07	Buy - Neutral	Downgraded by	HC Wainwright	$21.23	$43.00 → $18.00
2021-04-06	Outperform	Target Lowered by	SVB Leerink	$20.64	$63.00 → $31.00
2021-04-06	Buy - Hold	Downgraded by	Jefferies Financial Group	$20.64	$40.00 → $21.00
2021-04-06	Buy - Hold	Downgraded by	Canaccord Genuity	$20.64
2021-04-06	Buy - Neutral	Downgraded by	Mizuho	$20.64	$37.00 → $25.00
2021-04-06	Overweight	Target Raised by	Cantor Fitzgerald	$20.64	$33.00 → $45.00
2021-04-06	Buy - Hold	Downgraded by	Canaccord Genuity	$20.64	$40.00 → $26.00
2021-04-06	Overweight	Target Lowered by	Morgan Stanley	$20.64	$50.00 → $28.00
2021-04-05	Buy - Neutral	Downgraded by	The Goldman Sachs Group	$21.18
2021-04-05	Buy	Target Lowered by	Needham & Company LLC	$21.18	$44.00 → $30.00
2021-04-05	Outperform - Market Perform	Downgraded by	Raymond James	$21.18
2021-03-16	Buy - Neutral	Reiterated by	Bank of America	$27.34
2021-03-15	Buy - Hold	Reiterated by	Stifel Nicolaus	$29.99	$68.00 → $27.00
2021-03-15	Buy	Target Lowered by	HC Wainwright	$29.99	$60.00 → $43.00
2021-03-15	Overweight	Target Lowered by	Morgan Stanley	$29.99	$65.00 → $50.00
2021-03-15	Strong-Buy - Outperform	Reiterated by	Raymond James	$29.99	$65.00 → $35.00
2021-03-15	Buy	Target Lowered by	Needham & Company LLC	$29.99	$60.00 → $44.00
2021-03-15	Buy - Neutral	Reiterated by	Citigroup	$29.99	$66.00 → $35.00
2021-03-15	Buy - Neutral	Reiterated by	Guggenheim	$29.99
2021-03-15	Buy	Target Lowered by	Canaccord Genuity	$29.99	$61.00 → $40.00
2021-03-15	Buy - Neutral	Reiterated by	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	$29.99	$66.00 → $35.00
2021-03-10	Buy - Neutral	Downgraded by	Bank of America	$26.89
2021-03-09	Buy	Target Lowered by	Mizuho	$25.02	$70.00 → $55.00
2021-03-09	Strong-Buy - Outperform	Downgraded by	Raymond James	$25.02	$65.00 → $35.00
2021-03-09	Buy - Hold	Downgraded by	Stifel Nicolaus	$25.02	$68.00 → $27.00
2021-03-09	Buy	Target Lowered by	Needham & Company LLC	$25.02	$60.00 → $44.00
2021-03-09	Outperform	Reiterated by	Royal Bank of Canada	$25.02	$60.00 → $36.00
2021-03-09	Buy	Target Lowered by	HC Wainwright	$25.02	$60.00 → $43.00
2021-03-09	Buy - Neutral	Downgraded by	Guggenheim	$25.02
2021-03-09	Buy - Neutral	Downgraded by	Citigroup	$25.02	$66.00 → $35.00
2021-03-09	Buy	Reiterated by	Canaccord Genuity	$25.02	$61.00 → $40.00
2021-03-09	Market Perform	Target Lowered by	Oppenheimer	$25.02	$42.00 → $28.00
2021-03-09	Outperform	Target Lowered by	Cowen	$25.02	$66.00 → $57.00
2021-03-09	Overweight	Target Lowered by	Morgan Stanley	$25.02	$65.00 → $50.00
2021-03-09	Outperform	Target Lowered by	Royal Bank of Canada	$25.02	$60.00 → $36.00
2021-03-09	Buy	Target Lowered by	Canaccord Genuity	$25.02	$61.00 → $40.00
2021-03-03	Overweight	Target Raised by	Morgan Stanley	$47.44	$60.00 → $65.00
2021-03-02	Outperform	Target Raised by	Royal Bank of Canada	$46.94	$55.00 → $63.00
2021-02-25	Overweight	Reiterated by	Morgan Stanley	$47.31	$60.00 → $65.00
2021-02-25	Overweight	Target Raised by	Morgan Stanley	$47.31	$60.00 → $65.00
2021-02-24	Buy	Reiterated by	Mizuho	$48.69
2020-12-29	Overweight	Reiterated by	Cantor Fitzgerald	$53.78	$61.00 → $70.00
2020-12-16	Overweight	Target Raised by	Morgan Stanley	$53.08	$58.00 → $60.00
2020-12-15	Buy	Initiated by	Mizuho	$52.57	$69.00
2020-12-15	Buy	Initiated by	Mizuho	$52.57
2020-11-16	Outperform - Strong-Buy	Upgraded by	Raymond James	$54.63	$65.00
2020-11-05	Overweight	Target Raised by	Morgan Stanley	$48.56	$57.00 → $58.00
2020-10-13	Overweight	Target Raised by	Morgan Stanley	$43.26	$55.00 → $57.00
2020-08-24	Outperform	Initiated by	Raymond James	$38.00
2020-08-20	Overweight	Initiated by	Morgan Stanley	$39.27	$55.00
2020-08-06	Buy	Reiterated by	HC Wainwright	$43.63
2020-08-06	Buy	Reiterated by	Needham & Company LLC	$43.63	$60.00
2020-08-06	Buy	Target Raised by	Canaccord Genuity	$43.63	$56.00 → $60.00
2020-08-06	Outperform	Target Lowered by	SVB Leerink	$43.63	$56.00 → $52.00
2020-08-06	Hold	Reiterated by	Oppenheimer	$43.63	$42.00
2020-07-28	Hold	Reiterated by	Canaccord Genuity	$43.15	$29.00
2020-07-21		Target Lowered by	Citigroup	$44.69	$69.00 → $63.00
2020-07-21	Overweight	Target Lowered by	Cantor Fitzgerald	$44.69	$63.00 → $61.00
2020-07-21	Positive - Market Perform	Target Lowered by	Oppenheimer	$44.69	$53.00 → $42.00
2020-07-21	Outperform	Target Lowered by	Royal Bank of Canada	$44.69	$61.00 → $55.00
2020-07-21	Buy	Reiterated by	Jefferies Financial Group	$44.69	$60.00
2020-07-16	Buy	Initiated by	Needham & Company LLC	$54.58	$60.00
2020-07-09	Positive - Outperform	Target Raised by	Royal Bank of Canada	$56.07	$58.00 → $61.00
2020-07-06	Hold - Buy	Upgraded by	Stifel Nicolaus	$53.69	$41.00 → $71.00
2020-05-27	Market Perform	Target Raised by	Oppenheimer	$50.63	$48.00 → $53.00
2020-05-08	Buy	Reiterated by	Needham & Company LLC	$50.72
2020-05-08	Buy	Reiterated by	Cantor Fitzgerald	$50.72	$58.00 → $63.00
2020-05-08	Overweight	Target Raised by	JPMorgan Chase & Co.	$50.72	$50.00 → $55.00
2020-05-08	Hold	Reiterated by	Oppenheimer	$50.72	$48.00
2020-04-16	Buy	Initiated by	Jefferies Financial Group	$46.55	$60.00

ACAD Stock Trend

The stock lies the upper part of a wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $16.81 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -39.94% during the next 3 months and, with a 90% probability hold a price between $8.64 and $10.10 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$14.20	$15.42	$16.63
2021-09-21	$14.03	$15.24	$16.45
2021-09-22	$13.85	$15.06	$16.28
2021-09-23	$13.67	$14.89	$16.10
2021-09-24	$13.49	$14.71	$15.92
2021-09-27	$13.32	$14.53	$15.74
2021-09-28	$13.14	$14.35	$15.57
2021-09-29	$12.96	$14.18	$15.39
2021-09-30	$12.78	$14.00	$15.21
2021-10-01	$12.61	$13.82	$15.03
2021-10-04	$12.43	$13.64	$14.86
2021-10-05	$12.25	$13.47	$14.68
2021-10-06	$12.07	$13.29	$14.50
2021-10-07	$11.90	$13.11	$14.32
2021-10-08	$11.72	$12.93	$14.15
2021-10-11	$11.54	$12.76	$13.97
2021-10-12	$11.36	$12.58	$13.79
2021-10-13	$11.19	$12.40	$13.62
2021-10-14	$11.01	$12.22	$13.44
2021-10-15	$10.83	$12.05	$13.26
2021-10-18	$10.66	$11.87	$13.08
2021-10-19	$10.48	$11.69	$12.91
2021-10-20	$10.30	$11.51	$12.73
2021-10-21	$10.12	$11.34	$12.55
2021-10-22	$9.95	$11.16	$12.37
2021-10-25	$9.77	$10.98	$12.20
2021-10-26	$9.59	$10.80	$12.02
2021-10-27	$9.41	$10.63	$11.84
2021-10-28	$9.24	$10.45	$11.66
2021-10-29	$9.06	$10.27	$11.49

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzh... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!